Recent Quotes (30 days)

You have no recent quotes
chg | %

Resverlogix Corp.  

(Public, TSE:RVX)   Watch this stock  
Find more results for RVX
+0.05 (2.51%)
Oct 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.96 - 2.05
52 week 1.10 - 2.52
Open 1.96
Vol / Avg. 12,675.00/67,004.00
Mkt cap 213.29M
P/E     -
Div/yield     -
EPS -0.36
Shares 105.21M
Beta 0.98
Inst. own     -
Sep 14, 2016
Q2 2016 Resverlogix Corp Earnings Release
Sep 13, 2016
Resverlogix Corp at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Jul '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.04% -64.37%
Return on average equity - -
Employees 27 -
CDP Score - -


300-4820 Richard Rd SW
+1-403-2549252 (Phone)
+1-403-2568495 (Fax)

Website links


Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.

Officers and directors

Donald J. McCaffrey Chairman of the Board, President, Chief Executive Officer, Secretary
A. Brad Cann Chief Financial Officer
Jan O. Johansson M.D. Ph.D. Senior Vice President - Medical Affairs
Kenneth Lebioda Senior Vice President - Business & Corporate Development
Michael T. Sweeney M.D. Senior Vice President - Clinical Development
Norman Wong M.D. Chief Scientific Officer
Eldon R. Smith M.D. Lead Director
Age: 75
Norma K. Biln Director
Shawn Lu Director
Kelly B. McNeill Independent Director